{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:54:46Z","timestamp":1791474886918,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010828","name":"International Psychogeriatric Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010828","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.inpsyc.2025.100133","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T17:07:41Z","timestamp":1756141661000},"page":"100133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5501-3613","authenticated-orcid":false,"given":"Andrew A.","family":"Namasivayam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne E.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6490-6037","authenticated-orcid":false,"given":"Byron","family":"Creese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paula","family":"Gastiazoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana P.","family":"Hermida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-3731","authenticated-orcid":false,"given":"Zahinoor","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3922-2164","authenticated-orcid":false,"given":"Dilip V.","family":"Jeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"McDermid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-3514","authenticated-orcid":false,"given":"Kathryn","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Peschin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Margriet","family":"Pot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-3638","authenticated-orcid":false,"given":"Jacobo","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the cache county study","volume":"23","author":"Steinberg","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100133_bib2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jagp.2020.09.002","article-title":"Criteria for psychosis in major and mild neurocognitive disorders: international psychogeriatric association (IPA) consensus clinical and research definition","volume":"28","author":"Cummings","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41582-021-00597-3","article-title":"Psychosis in alzheimer disease \u2014 mechanisms, genetics and therapeutic opportunities","volume":"18","author":"Ismail","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/brain\/awaa413","article-title":"Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms","volume":"144","author":"Naasan","year":"2021","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3233\/JAD-190828","article-title":"Revisiting criteria for psychosis in Alzheimer\u2019s disease and related dementias: toward better phenotypic classification and biomarker research","volume":"73","author":"Fischer","year":"2020","journal-title":"J Alzheimer\u2019S Dis"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S1041610218000534","article-title":"Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: an international delphi consensus","volume":"31","author":"Kales","year":"2019","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib7","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia","volume":"2022","author":"M\u00fchlbauer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00019442-200002000-00004","article-title":"Psychosis of Alzheimer\u2019s disease and related dementias: diagnostic criteria for a distinct syndrome","volume":"8","author":"Jeste","year":"2000","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1192\/bjp.2019.195","article-title":"The individual course of neuropsychiatric symptoms in people with Alzheimer\u2019s and lewy body dementia: 12-year longitudinal cohort study","volume":"216","author":"Vik-Mo","year":"2020","journal-title":"Br J Psychiatry"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1017\/S1041610297004523","article-title":"A detailed phenomenological comparison of complex visual hallucinations in dementia with lewy bodies and Alzheimer\u2019s disease","volume":"9","author":"Ballard","year":"1997","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s44220-023-00043-x","article-title":"A longitudinal study of late-life psychosis and incident dementia and the potential effects of race and cognition","volume":"1","author":"Ismail","year":"2023","journal-title":"Nat Ment Health"},{"issue":"17","key":"10.1016\/j.inpsyc.2025.100133_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3233\/JAD-215483","article-title":"Psychosis as a treatment target in dementia: a roadmap for designing interventions","volume":"88","author":"Ag\u00fcera-Ortiz","year":"2022","journal-title":"J Alzheimer\u2019S Dis"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hbm.22248","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease are related to functional connectivity alterations in the salience network","volume":"35","author":"Balthazar","year":"2014","journal-title":"Hum Brain Mapp"},{"issue":"7","key":"10.1016\/j.inpsyc.2025.100133_bib15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.30773\/pi.2020.0009","article-title":"The relationship between neuropsychiatric symptoms and Default-Mode network connectivity in Alzheimer\u2019s disease","volume":"17","author":"Lee","year":"2020","journal-title":"Psychiatry Invest"},{"issue":"10","key":"10.1016\/j.inpsyc.2025.100133_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jagp.2019.03.020","article-title":"Delusions in alzheimer disease are associated with decreased default mode network functional connectivity","volume":"27","author":"Qian","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41398-022-01850-z","article-title":"Increased retention of tau PET ligand [18F]-AV1451 in Alzheimer\u2019s disease psychosis","volume":"12","author":"Gomar","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100133_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/01.wnl.0000341932.21961.f3","article-title":"Increased striatal dopamine (D2\/D3) receptor availability and delusions in alzheimer disease","volume":"72","author":"Reeves","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuroimage.2008.01.010","article-title":"Nicotinic alpha4beta2 receptor binding in dementia with lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations","volume":"40","author":"O\u2019Brien","year":"2008","journal-title":"Neuroimage"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3233\/JAD-131166","article-title":"Hyperphosphorylated tau is elevated in Alzheimer\u2019s disease with psychosis","volume":"39","author":"Murray","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.inpsyc.2025.100133_bib22","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.neurobiolaging.2014.03.003","article-title":"Psychotic Alzheimer\u2019s disease is associated with gender-specific tau phosphorylation abnormalities","volume":"35","author":"Koppel","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"10","key":"10.1016\/j.inpsyc.2025.100133_bib23","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1176\/appi.ajp.2013.13040466","article-title":"Elevated CSF tau is associated with psychosis in Alzheimer\u2019s disease","volume":"170","author":"Koppel","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100133_bib24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamapsychiatry.2024.1389","article-title":"Psychosis in alzheimer disease and elevations in Disease-Relevant biomarkers","volume":"81","author":"Gomar","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WAD.0000000000000250","article-title":"Psychosis in \u201cCognitively Asymptomatic\u201d elderly subjects is associated with neuritic plaque load, not neurofibrillary tangles","volume":"32","author":"Kim","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100133_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031947","article-title":"Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study","volume":"9","author":"Goukasian","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/JAD-150606","article-title":"Lewy bodies, vascular risk factors, and subcortical arteriosclerotic leukoencephalopathy, but not alzheimer pathology, are associated with development of psychosis in Alzheimer\u2019s disease","volume":"50","author":"Fischer","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100133_bib28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jnnp-2018-318445","article-title":"Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer\u2019s disease","volume":"90","author":"Vik-Mo","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100133_bib29","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.25739","article-title":"Frontotemporal dementia: correlations between psychiatric symptoms and pathology","volume":"87","author":"Scarioni","year":"2020","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.inpsyc.2025.100133_bib30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biopsych.2013.08.020","article-title":"Psychosis in Alzheimer\u2019s disease","volume":"75","author":"Murray","year":"2014","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-019-0519-7","article-title":"Visual hallucinations in Alzheimer\u2019s disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but May be associated with reduced cholinergic input to these areas","volume":"11","author":"Sinclair","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100133_bib32","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1531-8249(200012)48:6<868::AID-ANA7>3.0.CO;2-0","article-title":"Delusions associated with elevated muscarinic binding in dementia with lewy bodies","volume":"48","author":"Ballard","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbr.2005.02.019","article-title":"Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with lewy bodies","volume":"161","author":"Teaktong","year":"2005","journal-title":"Behav Brain Res"},{"issue":"7","key":"10.1016\/j.inpsyc.2025.100133_bib34","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00019442-200507000-00011","article-title":"Heritability of psychosis in alzheimer disease","volume":"13","author":"Bacanu","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"10.1016\/j.inpsyc.2025.100133_bib35","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/s41380-021-01152-8","article-title":"Genome-wide association identifies the first risk loci for psychosis in alzheimer disease","volume":"26","author":"DeMichele-Sweet","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib36","article-title":"Genetic associations with psychosis and affective disturbance in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: translational research & clinical interventions","volume":"10","author":"Antonsdottir","year":"2024"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib37","article-title":"A data-driven examination of apathy and depressive symptoms in dementia with independent replication","volume":"15","author":"Vasconcelos Da Silva","year":"2023","journal-title":"Alzheimer\u2019S Dement Diagn Assess Dis Monit"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100133_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2174\/1567205014666170220150021","article-title":"Gender and Pathology-Specific effect of apolipoprotein e genotype on psychosis in Alzheimer\u2019s disease","volume":"14","author":"Kim","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.inpsyc.2025.100133_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neurobiolaging.2020.01.001","article-title":"Psychosis-associated DNA methylomic variation in Alzheimer\u2019s disease cortex","volume":"89","author":"Pishva","year":"2020","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14501","article-title":"A brain DNA co-methylation network analysis of psychosis in Alzheimer\u2019s disease","volume":"21","author":"Kouhsar","year":"2025","journal-title":"Alzheimer\u2019S Dement"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41398-019-0592-5","article-title":"Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer\u2019s disease","volume":"9","author":"Creese","year":"2019","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41398-024-02878-z","article-title":"Unique transcriptional signatures correlate with behavioral and psychological symptom domains in Alzheimer\u2019s disease","volume":"14","author":"Fisher","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.inpsyc.2025.100133_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.778419","article-title":"Psychosis in Alzheimer\u2019s disease is associated with increased excitatory neuron vulnerability and Post-transcriptional mechanisms altering synaptic protein levels","volume":"13","author":"DeChellis-Marks","year":"2022","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s42003-023-04961-5","article-title":"Targeting the post-synaptic proteome has therapeutic potential for psychosis in alzheimer disease","volume":"6","author":"Krivinko","year":"2023","journal-title":"Commun Biol"},{"issue":"5","key":"10.1016\/j.inpsyc.2025.100133_bib45","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jamda.2024.03.007","article-title":"Guideline recommendations on behavioral and psychological symptoms of dementia: a systematic review","volume":"25","author":"Watt","year":"2024","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002500","article-title":"Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial","volume":"15","author":"Ballard","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.inpsyc.2025.100133_bib48","article-title":"Impact of the WHELD\/Brief psychosocial therapy intervention on psychosis in people with dementia: a cluster randomized trial","author":"Ballard","year":"2024","journal-title":"medRxiv"},{"issue":"9","key":"10.1016\/j.inpsyc.2025.100133_bib49","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/gps.4958","article-title":"An intervention to reduce neuropsychiatric symptoms and caregiver burden in dementia: preliminary results from a randomized trial of the tailored activity program\u2013outpatient version","volume":"34","author":"de Oliveira","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/ggi.12126","article-title":"Non-pharmacological treatment reducing not only behavioral symptoms, but also psychotic symptoms of older adults with dementia: a prospective cohort study in Taiwan","volume":"14","author":"Chen","year":"2014","journal-title":"Geriatr Gerontol Int"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.wad.0000126618.98867.fc","article-title":"The effect of a structured intervention on caregivers of patients with dementia and problem behaviors: a randomized controlled pilot study","volume":"18","author":"Nobili","year":"2004","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.inpsyc.2025.100133_bib52","article-title":"Non-pharmacological interventions for psychotic symptoms in people with dementia: a delphi consensus","author":"Choi","year":"2024","journal-title":"medRxiv"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100133_bib53","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/jgs.13558","article-title":"Effect of active music therapy and individualized listening to music on dementia: a multicenter randomized controlled trial","volume":"63","author":"Raglio","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10.1016\/j.inpsyc.2025.100133_bib54","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia","volume":"15","author":"Pollock","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.inpsyc.2025.100133_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","article-title":"Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: evidence from the CitAD study","volume":"173","author":"Leonpacher","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/YIC.0000000000000401","article-title":"Medicare claims analysis of agents used to manage dementia-related psychosis: a treatment pattern study","volume":"37","author":"Rashid","year":"2022","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.inpsyc.2025.100133_bib57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer\u2019s disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"7497","key":"10.1016\/j.inpsyc.2025.100133_bib58","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bmj.330.7497.922-c","article-title":"FDA warns about using antipsychotic drugs for dementia","volume":"330","author":"Lenzer","year":"2005","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.inpsyc.2025.100133_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/pn.43.14.0001","article-title":"FDA extends Black-Box warning to all antipsychotics","volume":"43","author":"Yan","year":"2008","journal-title":"Psychiatr N"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.inpsyc.2025.100133_bib61","unstructured":"Duke-Margolis Institute for Health Policy. Mortality and Antipsychotic Use in Dementia-Related Behavioral Disorders Meeting Summary [Internet]. 2025 [cited 2025 Apr 4]. Available from: \u3008https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2025-03\/Meeting%20Summary_Mortality%20and%20Antipsychotic%20Use%20in%20Dementia-Related%20Behavioral%20Disorders.docx.pdf\u3009."},{"issue":"9916","key":"10.1016\/j.inpsyc.2025.100133_bib62","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in Dementia-Related psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.inpsyc.2025.100133_bib65","unstructured":"Acadia Pharmaceuticals. Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis [Internet]. 2021 [cited 2025 Apr 4]. Available from: \u3008https:\/\/acadia.com\/en-us\/media\/news-releases\/acadia-pharmaceuticals-receives-complete-response-letter-us-0\u3009."},{"issue":"S10","key":"10.1016\/j.inpsyc.2025.100133_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/alz.062364","article-title":"Efficacy and safety of pimavanserin in patients with Alzheimer\u2019s dementia psychosis in the HARMONY phase 3, randomized discontinuation study: a post hoc subgroup analysis","volume":"18","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019S Dement"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100133_bib67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.inpsyc.2025.100133_bib68","unstructured":"Acadia Pharmaceuticals. Acadia Pharmaceuticals Announces Label Update for NUPLAZID\u00ae (pimavanserin) [Internet]. 2023 [cited 2025 Apr 4]. Available from: \u3008https:\/\/acadia.com\/en-us\/media\/news-releases\/acadia-pharmaceuticals-announces-label-update-for-nuplazid-pimavanserin\u3009."},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib69","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mdc3.13652","article-title":"Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among Medicare beneficiaries with Parkinson\u2019s disease psychosis","volume":"10","author":"Alipour-Haris","year":"2023","journal-title":"Mov Disord Clin Pr"},{"issue":"10","key":"10.1016\/j.inpsyc.2025.100133_bib70","doi-asserted-by":"crossref","first-page":"898.e1","DOI":"10.1016\/j.jamda.2015.06.021","article-title":"Impact of current antipsychotic medications on comparative mortality and adverse events in people with parkinson disease psychosis","volume":"16","author":"Ballard","year":"2015","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/14728214.2024.2363215","article-title":"Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer\u2019s disease","volume":"29","author":"Wang","year":"2024","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100133_bib72","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"issue":"10422","key":"10.1016\/j.inpsyc.2025.100133_bib73","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100133_bib74","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamaneurol.2023.1835","article-title":"Cholinesterase inhibitors for treatment of psychotic symptoms in alzheimer disease and parkinson disease: a Meta-analysis","volume":"80","author":"d\u2019Angremont","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100133_bib75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jagp.2019.06.008","article-title":"Do acetylcholinesterase inhibitors prevent or delay psychotropic prescribing in people with dementia? Analyses of the Swedish dementia registry","volume":"28","author":"Tan","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100133_bib76","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awaa438","article-title":"The development and convergence of co-pathologies in Alzheimer\u2019s disease","volume":"144","author":"Robinson","year":"2021","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.inpsyc.2025.100133_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12091266","article-title":"Determining whether sex and zygosity modulates the association between APOE4 and psychosis in a Neuropathologically-Confirmed Alzheimer\u2019s disease cohort","volume":"12","author":"Valcic","year":"2022","journal-title":"Brain Sci"},{"issue":"5","key":"10.1016\/j.inpsyc.2025.100133_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/gps.5711","article-title":"Psychiatric disorders and risk of subsequent dementia: systematic review and meta-analysis of longitudinal studies","volume":"37","author":"Stafford","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.inpsyc.2025.100133_bib79","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \u201cBenign Hallucinations\u201d in parkinson disease","volume":"63","author":"Goetz","year":"2006","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100133_bib80","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jamda.2021.12.031","article-title":"Optimizing practices, use, care, and Services-Antipsychotics (OPUS-AP) in Long-Term care centers in quebec, Canada: a successful Scale-Up","volume":"23","author":"Cossette","year":"2022","journal-title":"J Am Med Dir Assoc"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610225003710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610225003710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:39:05Z","timestamp":1772879945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610225003710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":80,"alternative-id":["S1041610225003710"],"URL":"https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100133","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Psychogeriatric Association.","name":"copyright","label":"Copyright"}],"article-number":"100133"}}